Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304190 | 0.83 | ESR1 (0.50) | ESR1ESR2ACHEHDAC4HDAC2 | |
| SCHEMBL134474 | 0.81 | HDAC8 (0.47) | ESR1ESR2ACHEHDAC4HDAC2 | |
| SCHEMBL26068824 | 0.79 | ACHE (0.36) | ESR1ESR2ACHEHDAC4HDAC2 | |
| SCHEMBL26811585 | 0.79 | ESR1 (0.34) | ESR1ESR2HDAC4HDAC2HDAC8 | |
| SCHEMBL5669662 | 0.78 | CNR1 (0.42) | ESR1ESR2ACHEHDAC4HDAC2 | |
| SCHEMBL4251026 | 0.78 | ESR1 (0.52) | ESR1ESR2ACHEHDAC4HDAC2 | |
| SCHEMBL17864482 | 0.78 | RXRA (0.47) | ESR1NR4A2KCNH2SYKMEN1 | |
| SCHEMBL18243516 | 0.77 | FAAH (0.39) | ESR1ESR2ACHEHDAC4HDAC2 | |
| SCHEMBL30148546 | 0.77 | TAS1R3 (0.37) | ESR1ESR2ACHETP53BP1KCNH2 | |
| SCHEMBL6899596 | 0.77 | TAS1R3 (0.37) | ESR1ESR2ACHETP53BP1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108690164-B | Acid-cleavable monomers and polymers comprising the same | 罗门哈斯电子材料有限责任公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-112533913-A | Novel compounds | 英夫拉索姆有限公司 | 2021-03-19 | — | — | CN | disclosed |
| EP-3788041-A1 | NOVEL COMPOUNDS | Inflazome Limited (IE) | 2021-03-10 | — | — | EP | disclosed |
| CN-108690164-A | Sour cleavable monomer and the polymer including it | 罗门哈斯电子材料有限责任公司 | 2018-10-23 | — | — | CN | disclosed |
| US-10095109-B1 | Acid-cleavable monomer and polymers including the same | ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180284605-A1 | ACID-CLEAVABLE MONOMER AND POLYMERS INCLUDING THE SAME | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2018-10-04 | — | — | US | disclosed |
| US-20090105234-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK & CO., INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090105234-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK & CO., INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090105234-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK & CO., INC. | 2009-04-23 | — | — | US | disclosed |
| CN-100439366-C | Pyrido[2,3-d]pyrimidine-2,4-diamines as PDE2 inhibitors | PFIZER PROD INC (US) | 2008-12-03 | — | — | CN | disclosed |
| EP-1912977-A1 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | Merck Frosst Canada Ltd. (CA) | 2008-04-23 | — | — | EP | disclosed |
| EP-1697356-B1 | PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS | PFIZER PROD INC (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070135457-A1 | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde2 inhibitors | PFIZER INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2007014454-A1 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | MERCK FROSST CANADA LTD. (CA) | 2007-02-08 | — | — | WO | disclosed |
| CN-1894245-A | Pyrido[2,3-d]pyrimidine-2,4-diamines as PDE2 inhibitors | PFIZER PROD INC (US) | 2007-01-10 | — | — | CN | disclosed |
| EP-1697356-A1 | PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS | Pfizer Products Incorporated (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005061497-A1 | PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180284605-A1 | ACID-CLEAVABLE MONOMER AND POLYMERS INCLUDING THE SAME | FURIN, IDUA, ADAM9 | ESR1 820/4885ESR2 2764/4885ACHE 1617/4885 |
| US-10095109-B1 | Acid-cleavable monomer and polymers including the same | FURIN, IDUA, ADAM9 | ESR1 820/4885ESR2 2764/4885ACHE 1617/4885 |
| US-20070135457-A1 | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde2 inhibitors | PDE12, PDE2A, PDE3A | ESR1 3705/4885ESR2 2381/4885ACHE 319/4885 |
| US-20090105234-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | PTGER4, PTGER1, PTGER3 | ESR1 221/4885ESR2 106/4885ACHE 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.